Abstract
Diabetic gastroparesis (DGp) is associated with severe symptoms, impaired quality of life, and significant health care utilization.1 Treatment of DGp remains unsatisfactory. Metoclopramide is the only Food and Drug Administration–approved medication for gastroparesis. Gastric electrical stimulation is approved for compassionate use in refractory patients; however, it is invasive, lacks robust supporting evidence, does not consistently improve symptoms, and is associated with serious adverse events.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
